Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
about
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart AssociationHepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Optimizing drug development in oncology by clinical trial simulation: Why and how?Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Kinase Inhibitors: The Reality Behind the Success.
P2860
Q30359686-41D8B884-8D3F-46B1-8CF2-772F2809DB35Q35812091-8023A0C7-F9BF-4F50-8A12-2D1F3C3FDAA9Q36463168-ADBB3A09-CA9E-4D31-888D-F6C0CCC039A2Q38167808-E9E16DE0-A268-4290-98F8-7778B23360B9Q38501976-88C031DB-E4AA-425D-90B3-EA8D59FFAF2AQ38675644-BF268922-E9F8-44FE-9640-DD0955F6C176Q38937228-0C0F6476-565C-415F-84A5-C57EEF43520DQ39102535-C89C1FB7-DD86-44F4-8852-A66CCAE3B499Q40670954-49A1D9EE-2669-441E-811D-FC1F566554E4Q46431899-6636E160-DA4B-4F5E-AB35-4B6E5579B26FQ47970146-FC931B00-BF21-4AAA-84AC-C157402D4F11
P2860
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@en
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@nl
type
label
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@en
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@nl
prefLabel
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@en
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@nl
P2093
P2860
P356
P1476
Integrating clinical pharmacol ...... th tyrosine kinase inhibitors.
@en
P2093
A Sparreboom
C D Drenberg
P2860
P2888
P304
P356
10.1038/CLPT.2012.247
P407
P577
2013-03-01T00:00:00Z
P5875
P6179
1043782698